[{"address1": "4000 Shoreline Court", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 822 5600", "website": "https://www.kezarlifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 55, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher J. Kirk Ph.D.", "age": 52, "title": "Co-Founder, CEO & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 927300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Franklin Fowler", "age": 52, "title": "Co-Founder & Director", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 57037, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Schiller", "age": 44, "title": "Chief Operations Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 637985, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack  Taunton Ph.D.", "title": "Co-Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pattie  Chiang", "age": 62, "title": "Principal Accounting Officer, Senior VP & Corporate Controller", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gitanjali  Jain", "title": "Senior Vice President of Investor Relations & External Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joe  Tedrick", "title": "Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neel K. Anand Ph.D.", "title": "Senior Vice President of Research & Drug Discovery", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zung  To", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel  Peterson FACR, M.D.", "title": "Head of Clinical Immunology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.75, "open": 3.8, "dayLow": 3.64, "dayHigh": 3.8, "regularMarketPreviousClose": 3.75, "regularMarketOpen": 3.8, "regularMarketDayLow": 3.64, "regularMarketDayHigh": 3.8, "payoutRatio": 0.0, "beta": 0.605, "forwardPE": -0.34861508, "volume": 47836, "regularMarketVolume": 47836, "averageVolume": 48657, "averageVolume10days": 38210, "averageDailyVolume10Day": 38210, "bid": 2.74, "ask": 4.67, "bidSize": 2, "askSize": 2, "marketCap": 26729338, "fiftyTwoWeekLow": 3.62, "fiftyTwoWeekHigh": 9.2, "allTimeHigh": 363.3, "allTimeLow": 3.62, "fiftyDayAverage": 4.0066, "twoHundredDayAverage": 4.95735, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -62046664, "profitMargins": 0.0, "floatShares": 4314261, "sharesOutstanding": 7323106, "sharesShort": 762155, "sharesShortPriorMonth": 734466, "sharesShortPreviousMonthDate": 1755216000, "dateShortInterest": 1757894400, "sharesPercentSharesOut": 0.1041, "heldPercentInsiders": 0.10569999, "heldPercentInstitutions": 0.63956, "shortRatio": 21.91, "shortPercentOfFloat": 0.106300004, "impliedSharesOutstanding": 7323106, "bookValue": 12.546, "priceToBook": 0.2909294, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -70791000, "trailingEps": -9.7, "forwardEps": -10.47, "lastSplitFactor": "1:10", "lastSplitDate": 1730246400, "enterpriseToEbitda": 0.83, "52WeekChange": -0.52597404, "SandP52WeekChange": 0.1529237, "quoteType": "EQUITY", "currentPrice": 3.65, "targetHighPrice": 18.0, "targetLowPrice": 7.0, "targetMeanPrice": 12.5, "targetMedianPrice": 12.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 100849000, "totalCashPerShare": 13.771, "ebitda": -74738000, "totalDebt": 12073000, "quickRatio": 7.159, "currentRatio": 7.289, "debtToEquity": 13.153, "returnOnAssets": -0.32759, "returnOnEquity": -0.58391, "grossProfits": -54035000, "freeCashflow": -42026000, "operatingCashflow": -64304000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "KZR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Kezar Life Sciences, Inc.", "longName": "Kezar Life Sciences, Inc.", "fiftyTwoWeekLowChange": 0.03000021, "fiftyTwoWeekLowChangePercent": 0.008287351, "fiftyTwoWeekRange": "3.62 - 9.2", "fiftyTwoWeekHighChange": -5.5499997, "fiftyTwoWeekHighChangePercent": -0.6032609, "fiftyTwoWeekChangePercent": -52.597404, "earningsTimestampStart": 1763150400, "earningsTimestampEnd": 1763150400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -9.7, "epsForward": -10.47, "epsCurrentYear": -7.53333, "priceEpsCurrentYear": -0.4845135, "fiftyDayAverageChange": -0.3565998, "fiftyDayAverageChangePercent": -0.0890031, "twoHundredDayAverageChange": -1.3073497, "twoHundredDayAverageChangePercent": -0.26371947, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1758917403, "regularMarketTime": 1758916801, "exchange": "NCM", "messageBoardId": "finmb_304157325", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -2.66666, "regularMarketPrice": 3.65, "postMarketChangePercent": 0.0, "postMarketPrice": 3.65, "postMarketChange": 0.0, "regularMarketChange": -0.0999999, "regularMarketDayRange": "3.64 - 3.8", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 48657, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529587800000, "displayName": "Kezar Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-09-27"}]